Bendamustine Hydrochloride

Form: Injection (powder for solution)

Strength: 25 mg/vial, 100 mg/vial

Reference Brands: Treanda®, Bendeka®(US), Levact®(EU)

Category: Oncology Cancer Care

Bendamustine Hydrochloride Injection, available in 25 mg and 100 mg vials, is a widely used oncology API and formulation for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Marketed under brands like Treanda®, Bendeka®, and Levact® in the US and EU, it offers dual mechanisms of action—alkylation and antimetabolite activity—leading to potent cancer cell apoptosis. Ideal for pharmaceutical B2B sourcing, Bendamustine is supplied as a sterile powder or solution for IV infusion, suitable for hospitals and oncology treatment centers across regulated markets. GMP-certified manufacturing ensures quality compliance for international partnerships.